ArticleMultiple sclerosis journal - experimental, translational and clinical
Epidemiology of multiple sclerosis in a healthcare area of the Basque Country, Northern Spain: A population-based study (2009-2023).
Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple sclerosis (MS) prevalence has increased across Europe, yet contemporary population-based data from southern Europe remain scarce. Objectives: In this retrospective population-based cohort study conducted in a healthcare area of the Basque Country (Barrualde-Galdakao Integrated Healthcare Organisation [BGIHO]), northern Spain, we estimated prevalence, incidence, and clinical characteristics of MS. Prevalence was estimated on 31 December 2023 using the 2017 McDonald criteria, and incidence was assessed from 1 January 2009 to 31 December 2023 using both symptom-onset and diagnosis-based definitions. Results: Prevalence was 131.8 per 100,000 inhabitants (95% CI 119.6-145.2); age-adjusted prevalence (European Standard Population [ESP2013]) was 125.4 (95% CI 113.3-138.1). Mean annual incidence (2009-2023) was 4.4 per 100,000 person-years (95% CI 3.9-5.1) by symptom onset and 5.3 (95% CI 4.7-6.0) by diagnosis date. Relapsing-remitting MS (RRMS) accounted for 67.1% of cases; secondary progressive MS (SPMS) for 18.6%; and primary progressive MS (PPMS) for 14.2%. Median EDSS was 2 (IQR 0-5). Conclusions: MS prevalence in this healthcare area is high. The findings reflect an aging MS population with evolving clinical characteristics. The use of complementary incidence definitions provides insight into disease occurrence and healthcare detection. Continued epidemiological monitoring is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.